A woman dies every two minutes globally due to failures in maternal care, shocking new figures reveal
A woman dies every two minutes due to failures in maternal healthcare, according to shocking global data that has prompted stark warnings about the impact of cuts to aid funding by the US and the UK.
A new report from the World Health Organisation (WHO) has revealed that there were 260,000 maternal deaths in 2023, equating to 712 women a day or 30 per hour – with the vast majority in sub-Saharan Africa.
The WHO has warned that the global target for all UN member states to reduce maternal deaths – down to 71 per 100,000 by 2030 – will be missed by more than twice this amount as 'the pace of progress has slowed to a near standstill'.
Leading health organisations including the WHO have warned that recent sweeping cuts to international aid by the US government, which amount to more than £595m ($770m) for maternal health and family planning, will risk 'a shift backwards' in the progress made on cutting maternal deaths – defined as any death related to or aggravated by pregnancy, or within six weeks of the end of a pregnancy.
Speaking at a press conference, Dr Bruce Aylward, assistant director general of universal health coverage for the WHO, said: 'The funding cuts risk not only that progress, but we could have a shift backwards.' He said that cuts were already 'affecting access to lifesaving supplies and medicines, and especially treatments for some of the leading causes of maternal death'.
'One of the first things that they're seeing already is that countries are already laying off staff, or not hiring, or they're slowing down that healthworker spend... This is a real concern,' he added.
Some 60 countries worldwide are dependent on US-funded maternal care programmes and family planning services, largely concentrated in Africa and South Asia.
These programmes also provide funding for midwives in areas where essential maternal care is lacking. Reports from sources on the ground indicate that cancelling USAID contracts has led to some midwives losing their source of income, leaving women in the area without safe care during pregnancy.
But it's not just the US: aid cuts are happening around the world. In February, prime minister Sir Keir Starmer announced that the government would slash its aid spending from 0.5 per cent of national income to 0.3 per cent in 2027 – a cut of about £6bn – to pay for increased defence spending.
The announcement came after the government's International Development Committee (IDC) warned that UK aid cuts have already had a 'devastating' impact on women and girls, with young girls in Sudan more likely to die during pregnancy than finish school. Labour MP Sarah Champion, chair of the IDC, told The Independent: 'I remain deeply concerned that the cuts to aid will hit women's health hard and destroy all the hard-won progress around the world.'
She added: 'Preventing maternal deaths is not a medical mystery; we can end them with political commitment and financial investments. Realising the right to safe pregnancy and childbirth requires continued efforts to improve the quality of care, which must be backed by adequate financial resources and supportive laws ... Weak health systems and new and protracted humanitarian crises have led to stagnating results in several countries, and even reversals in some.'
The new WHO figures reveal that one in 36 15-year-old girls in west Africa is at risk of maternal death. This compares to 1 in 16,000 across southern Europe.
Since 2000, global maternal mortality rates have declined by 40 per cent, from 328 per 100,000 live births to 197 in 2023. However, the figures reveal inequalities across high- and low-income countries.
Dr Pascale Allotey, director of the Department of Sexual and Reproductive Health at the WHO, warned: 'Despite advances since 2000, the pace of progress has slowed to a near standstill. In some regions, we are already sliding backwards. In this context of fragility, complacency is not just dangerous, it is deadly ... When women die because of where they live, what they earn, or what rights are denied, it is indefensible, and it is preventable.'
According to the report, half of all maternal deaths in 2023 were recorded in Nigeria, India, the Democratic Republic of the Congo and Pakistan. Nigeria alone accounted for one in three deaths, with around 75,000 deaths in 2023, while 70 per cent of deaths occurred in sub-Saharan Africa.
The world's key international organisation focused on women's reproductive health, the United Nations Population Fund (UNFPA), has also warned that recent US funding cuts to aid will risk an increase in maternal death rates.
Estimates by UNFPA show that £71m ($92m) of US aid is distributed in Nigeria, where death rates are highest. UNPFA itself has lost £291m ($377m) in grants following the cuts to USAID.
Julia Bunting, programme director for UNFPA, told The Independent that, while there has been progress in reducing maternal deaths globally, it is 'by no means fast enough'. She said: 'We know there has been a 40 per cent decline in maternal death rates since 2000, but ... the progress is uneven and slowing.'
She added: 'These lives can be saved ... It's not just a matter of health. It's a matter of rights; it's a matter of justice. We believe every woman should deserve to survive childbirth ... We know how to prevent these deaths: with skilled midwives, quality care, and political commitment we can save very many of these lives, but there's a real urgent need for investment, so we don't risk reversing the gains that have already been made.'
Although UNFPA has faced cuts to its funding from USAID, Monica Ferro, director of the organisation's London representation office, confirmed that it has yet to have its funding cut by the UK, which is its second-biggest donor.
However, she warned: 'The combination of funding cuts, the increasing frequency of conflicts and the impacts of climate change mean pregnant women can't access lifesaving care, and gender-based violence is rising. We can't abandon the women and girls who need us most.'
The Cabinet Office was approached for comment.
A spokesperson for the Foreign Office said: 'We are committed to defending and promoting sexual and reproductive health and rights, and we will continue to work with international partners in support of women and girls.
'Aid is only one way in which we support this work, and we will continue to use targeted funding and diplomatic engagement to provide leadership on gender issues and maternal health.
'Protecting our national security is the first duty of any government, and doing so required the difficult but necessary decision to reduce our aid spending.'
A US state department spokesperson said that the US government has provided longstanding support to lifesaving maternal and child health services in lower-income countries where the vast majority – over 90 per cent – of all maternal and child deaths occur.
This report has been produced as part of The Independent's Rethinking Global Aid project

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Global Deferiprone Market to Hit Valuation of US$ 55.22 Million by 2033
Current Deferiprone market momentum reflects rising transfusion-related iron overload cases, broader regulatory approvals, generic competition lowering prices, formulation innovations improving adherence, positioning this critical chelator for sustained, diversified growth despite cost and safety challenges. Chicago, June 06, 2025 (GLOBE NEWSWIRE) -- The global deferiprone market was valued at US$ 39.89 million in 2024 and is expected to reach US$ 55.22 million by 2033, growing at a CAGR of 3.68% during the forecast period 2025–2033. Clinicians confronted with transfusion-dependent thalassemia major, sickle cell disease, myelodysplastic syndromes, and rare inherited anemias increasingly rely on iron chelation to prevent cardiomyopathy and hepatic failure. Against this backdrop, the Deferiprone market has become an indispensable component of comprehensive hematology care. The World Health Organization records roughly 63,000 births each year with homozygous β-thalassemia, while global registries list more than 300,000 newborns with sickle cell disease annually. Each patient can accumulate up to 0.3 grams of iron from a single red-cell transfusion, and many receive at least 20 transfusions per year, creating an urgent clinical mandate for efficient, orally available chelators. Download Sample Pages: Deferiprone, introduced three decades ago and now available in tablet, oral solution, and extended-release forms, remains the only bidentate chelator capable of accessing intracellular labile iron pools. Consequently, cardiologists report a tangible decline in transfusion-related cardiac deaths wherever routine chelation includes this agent. Recent meta-analyses covering 8,700 patient-years demonstrate a mean reduction of 5.6 micrograms per gram dry weight in hepatic iron when Deferiprone is combined with standard therapy, underscoring its synergistic potential. These hard clinical outcomes, rather than promotional narratives, underpin sustained growth of the market. Key Findings in Deferiprone Market Market Forecast (2033) US$ 55.22 million CAGR 3.60% Largest Region (2024) North America (40%) By Type Tablet (79%) By Therapeutics Use Iron Overload Disorders (40%) By Indication Transfusional Iron Overload (62%) Top Drivers Rising prevalence of transfusion-dependent anemias requiring iron chelation therapy. Increasing affordability through generic deferiprone production in developing regions. Expanding clinical indications, including neurodegenerative diseases and cardiac iron overload. Top Trends Development of extended-release formulations to improve patient compliance globally. Growing R&D investments in deferiprone for non-traditional therapeutic applications. Strategic collaborations between pharmaceutical companies to enhance global distribution networks. Top Challenges Limited awareness and diagnosis rates in low-income and rural regions. Competition from alternative iron chelators with established market presence. Regulatory hurdles for approval of new deferiprone formulations and indications. Incidence Data Highlights Unmet Needs Fueling Ongoing Clinical Demand Worldwide Drilling deeper into epidemiology exposes the granular patient pools that continually replenish the Deferiprone market. India's national thalassemia registry listed 99,258 transfusion-dependent individuals by February 2024, an increase of 4 600 cases over the preceding two years. China's southern provinces collectively treat about 88,000 comparable patients, according to Guangdong's Center for Genetic Blood Disorders. Meanwhile, the Eastern Mediterranean region follows closely with approximately 40,000 clinically significant cases managed across Egypt, Iran, and Greece. Because each thalassemic child consumes nearly 18 units of packed red cells annually, hematology day-care centers in these geographies order chelators at volumes previously seen only in tertiary Western hospitals. Parallel demand drivers emerge from sickle cell cohorts. Nigeria hosts an estimated 150,000 children living with severe sickle cell complications that necessitate regular exchange transfusion protocols; Democratic Republic of Congo manages close to 90 000 comparable cases. In the United States, the Centers for Disease Control and Prevention documents roughly 100,000 affected individuals, about 6 000 of whom are on chronic transfusion programs. Each exchange procedure introduces between 200 and 300 milligrams of additional iron, rapidly surpassing physiologic clearance thresholds. Without prompt chelation, organ damage progresses within five years of therapy initiation. This confluence of sizeable, transfusion-dependent populations sustains robust throughput across the Deferiprone market. Regulatory Milestones And Label Expansions Influence Competitive Positioning Dynamics Globally Regulators have steadily broadened clinical indications, materially altering how stakeholders appraise the Deferiprone market. The US Food and Drug Administration granted the molecule's first domestic approval in October 2011 for transfusional iron overload in thalassemia major, followed by an adolescent label extension in 2015. A further update in July 2022 introduced sickle cell disease and other chronic anemias to the prescribing information, effectively doubling the addressable patient pool. Europe mirrored this trajectory; the European Medicines Agency endorsed pediatric use down to six years in 2021, while Italy's AIFA added compassionate reimbursement for myelodysplastic syndromes in 2023 based on real-world registry data involving 312 adults. In parallel, authorities in Japan (May 2021) and South Korea (January 2024) issued marketing licenses after local bridging studies confirmed comparable pharmacokinetics to Ferriprox. China's National Medical Products Administration accepted Anhui Golden Sun's abbreviated dossier in March 2024, paving the way for the country's first domestic generic launch in early 2025. Each regulatory green light not only widens clinical access but also recalibrates competitive strategy, particularly for originator holder Chiesi Global Rare Diseases. As time-bound exclusivities expire, dossier approvals in emergent jurisdictions intensify price competition yet expand overall prescription volume, a dynamic that keeps the Deferiprone market fluid and opportunity-rich. Technological Innovations Elevate Formulation Convenience And Patient Adherence Metrics Substantially Product engineering advances now concentrate on reducing pill burden and mitigating gastrointestinal intolerance—two chief reasons patients abandon chelation, a persistent pain point for the Deferiprone market worldwide. A landmark 2023 study in Haematologica detailed how a once-daily 1,500 mg modified-release matrix reduced reported nausea episodes by 35 per thousand dosing days when compared with three-times-daily immediate-release tablets. The formulation, co-developed by Chiesi and Skyepharma, maintains serum trough concentrations above the 20 µmol/L threshold for eight continuous hours. Such pharmacokinetic smoothing aligns with contemporary adherence-support paradigms, and its commercial roll-out is already reshaping hospital formularies within the Deferiprone market. Parallel innovation is unfolding in digital therapeutics. Bluetooth-enabled smart bottle caps paired with HIPAA-compliant mobile applications now log real-time dosing events, transmit adherence alerts to clinicians, and integrate ferritin laboratory values imported from electronic health records. In a Cleveland Clinic pilot released April 2024, median adherence across 78 patients improved from 61 to 82 missed doses per year after deployment of the connected packaging. By fusing patient engagement technology with improved pharmacology, stakeholders are addressing both sides of the persistence equation. These synergistic advances enhance measurable outcomes and create differentiated value propositions inside the Deferiprone market. Regional Disparities Reveal Access Barriers And Emerging Distribution Partnerships Initiatives The geographical distribution of chelation therapy remains uneven, creating stark contrasts in treatment standards. Only 14 of Africa's 54 countries list deferiprone on national essential medicine schedules, and fewer than 25 tertiary centers on the continent possess consistent drug supply. Freight cost spikes—averaging 1,200 US dollars per pallet in 2023—contribute to recurrent shortages. To bridge the gap, the humanitarian consortium Global Blood Initiative entered a five-year memorandum with Chiesi in November 2023, committing 1.2 million tablet equivalents annually for donation to Uganda, Tanzania, and Ghana. Such public-private ventures broaden humanitarian visibility but capture only a fraction of pent-up demand within the Deferiprone market. Conversely, Latin America is charting collaborative distribution models that leverage regional manufacturing. Argentina's Akron Pharma began local blister production under license in late 2022, trimming delivery lead times from 90 to 28 days and reducing import duties. Brazil's Ministry of Health followed with a technology-transfer agreement, aiming to reach 12 state oncology centers by mid-2024. These initiatives dovetail with Pan-American Health Organization procurement platforms, boosting negotiating power and ensuring continuous stock. Successful replication of such frameworks across additional low-resource settings could dramatically level access inequities and unlock dormant segments of the Deferiprone market. Competitive Landscape Intensifies As Generics Challenge Established Brand Positioning Globally Chiesi's Ferriprox still holds leadership status, yet 2023 marked the arrival of formidable generic contenders that are recalibrating cost dynamics. Teva's USP-validated tablets gained final FDA approval in December 2023, followed by Hikma's submission acceptance in the European Union during February 2024. In India, where reverse-engineering prowess is well entrenched, at least seven Drug Controller General-approved brands—including Cipla's Sifinox and Natco's Ferinol—vie for hospital tenders. Wholesale acquisition costs now vary by up to 19 US dollars per gram across jurisdictions, underscoring widening price dispersion. This intensifying rivalry adds fresh complexity but also broadens affordability within the Deferiprone market. The originator is countering with value-added services rather than aggressive discounting. An expanded Ferriprox Total Care program launched in April 2024 bundles genetic counseling, adherence coaching, and free absolute neutrophil count monitoring for eligible US patients. In Europe, Chiesi is piloting an outcomes-based reimbursement contract with the National Health Service that ties payment tranches to serial ferritin and T2* cardiac MRI improvements. Meanwhile, smaller specialty firms are targeting niche subpopulations such as pyruvate kinase deficiency, hoping to differentiate beyond price. The collective result is a vibrant, multifactorial contest that keeps strategic stakes high across every layer of the Deferiprone market. Pipeline Exploration Broadens Therapeutic Horizons Beyond Hematology Core Applications Frontier Academic consortia have begun exploiting deferiprone's metal chelation profile to modulate neurodegenerative pathways characterized by aberrant iron deposition. The University of Melbourne's FAIR-PARK II trial enrolled 372 early-stage Parkinson's patients and reported in 2023 that twice-daily 30 mg/kg dosing slowed Unified Parkinson Disease Rating Scale motor score progression by 3.2 points over two years. Similarly, the Italian TIRCON network is running a 120-patient phase III study in neurodegeneration with brain iron accumulation, with interim analyses expected Q4 2024. Positive readouts could create fresh regulatory submissions and extend the Deferiprone market well beyond hematology clinics. Other exploratory fronts include a 60-patient US National Eye Institute protocol investigating retinal iron overload in age-related macular degeneration, and a multicenter French study assessing intravenous deferiprone for acute mucormycosis adjunctive therapy. While these indications are still nascent, they illustrate the molecule's mechanistic versatility and the appetite for repositioning small-molecule chelators. Investors tracking orphan-neurology spaces are already modeling incremental revenue accretion scenarios, contingent on phase III success. Should even one of these programs translate into approval, the Deferiprone market will witness a meaningful broadening of prescriber base, reinforcing long-term growth prospects. Request Report Customization: Future Outlook Balances Opportunities Against Pricing And Safety Constraints Ahead Looking toward 2033, stakeholders likely to anticipate that cumulative clinical evidence, label expansions, and digital adherence innovations will keep patient uptake on an upward trajectory. Annual global blood transfusion volumes surpassed 120 million units in 2024, and each incremental liter of packed cells revalidates the clinical rationale for chelation. Policy momentum is equally supportive; the World Bank's new Global Sickle Cell Strategy allocates 700 million US dollars over the next five years to holistic care packages that explicitly list oral iron chelators. These macro-level events establish a sturdy demand floor for the Deferiprone market. Nonetheless, certain headwinds deserve equal scrutiny. Neutropenia rates of 1.7 cases per thousand patient-months, documented in the 2024 Deferiprone Safety Consortium registry (n = 12 456), demand continued pharmacovigilance and proactive monitoring infrastructure. On the economics side, payer pressure is escalating; Germany's G-BA has initiated a benefit-assessment reassessment post generic entry, and India's National Pharmaceutical Pricing Authority is reviewing ceiling prices for chelation agents in 2025. These converging forces will oblige manufacturers to refine risk-management programs and optimize supply-chain efficiencies. Successfully navigating such constraints will delineate tomorrow's winners within the Deferiprone market. Global Deferiprone Market Key Players: Apotex Inc. Chiesi Farmaceutici S.p.A. Cipla Limited Novartis International AG Sun Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd. VHB Life Sciences Limited Zydus Other Prominent Players Key Segmentation: By Type Capsule Oral Solutions Tablets By Therapeutic Use Iron Overload Disorders Sickle Cell Disease Treatment Thalassemia Treatment By Indication NTDT Caused Overload Transfusional Iron Overload By Region North America Europe Asia Pacific Middle East & Africa (MEA) South America Need More Info? Ask Before You Buy: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTubeError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Brits issued Covid booster warning as cases of new strain rise
Brits have been urged to get their Covid booster jabs, as experts warned of a rise in cases following a recent spell of warm weather. The message comes after health experts also warned of a new COVID-19 variant, with cases of the strain are on the rise around the world. Covid NB.1.8.1 is a variation of the XDV.1.5.1 strain and was first detected back in January 2025. Ifti Khan, superintendent pharmacist at Well Pharmacy, urged those eligible to book as soon as possible and get the booster while it is still available. He said: 'Covid will most likely rise coming into the end of spring and into summer as people mix with friends and family more often. 'We know from previous boosters that they are effective in making sure that patients' symptoms are not as severe as they might have been without so I would urge patients to pop into their local Well Pharmacy store and get their jab. 'Patients have just over two weeks as the spring booster programme ends on June 17 so it would be my hope that those who can get a jab, opt to do so before enjoying socialising during summer.' Mr Khan warned that at this time of year, some people may believe they have hay fever as early symptoms of Covid include a runny or blocked nose or a sore throat. Covid tests can be obtained at any Well Pharmacy. The WHO has placed the Covid NB.1.8.1 "under monitoring" due to the rise in cases worldwide. It is one of six COVID-19 variants currently being monitored. The new 'Strategic and operational plan for coronavirus disease threat management: at a glance' sets out the global framework for supporting Member States in the sustained, integrated, evidence-based management of coronavirus disease threats, including #COVID19, MERS, and… — World Health Organization (WHO) (@WHO) May 28, 2025 However, the WHO stated that the risk posed by the new variant was "low," and that approved COVID-19 vaccines are expected to be effective against it. The world health experts, in a recent risk evaluation, said: "Despite a concurrent increase in cases and hospitalisations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation. The WHO added: "The available evidence on NB.1.8.1 does not suggest additional public health risks relative to the other currently circulating Omicron descendent lineages." COVID NB.1.8.1 has already been detected in 22 countries. These include the likes of Australia, China, Hong Kong, Thailand and the US, according to The Independent. The coming COVID-19 Winter Surge in Australia will show the world where we are actually headed is happening in South-Eats Asia and East Asia are just the 'preludes'...watch how NB.1.8.1 spawns are evolving including PQ.1, PQ.2 and even sub-lineages like PE.1. — Thailand Medical News (@ThailandMedicaX) June 4, 2025 Cases of the NB.1.8.1 variant have also been confirmed in Northern Ireland, Wales, and "popular British tourist hotspots", the news outlet added.
Yahoo
an hour ago
- Yahoo
What is driving a surge in COVID cases in India, other countries?
India has reported a sudden rise in COVID cases, starting from late May. Authorities said the number of active cases of the disease has surpassed 5,000. India is the latest of a number of countries to report an uptick in COVID cases this year as, more than five years after the virus was declared a global pandemic, waves of new strains continue to emerge. Here is what we know about the new variant of COVID and where it has spread: As of Thursday this week, there are 5,364 active cases in India, according to India's Ministry of Health and Family Welfare. Since January 1, more than 4,700 people have recovered from COVID in India, while 55 people have died from the virus. The main coronavirus variant causing a new spread of the disease is known as NB.1.8.1. Cases caused by this variant have been reported in the United Kingdom, the United States, Australia, Thailand, China and Hong Kong, among other countries. It is now the dominant variant in China and Hong Kong. A second variant, LF.7, is also responsible for some of the cases in India. The UK Health Security Agency (UKHSA) said it had recorded 13 cases of the NB.1.8.1 variant in England, with 'small numbers' detected across the UK. By late April, NB.1.8.1 comprised about 10.7 percent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 percent one month Omicron variant NB.1.8.1 was first detected in January this year. It is a 'recombinant' variant, which means it has arisen from the genetic mixing of two or more existing variants. On May 23, 2025, the WHO declared the NB.1.8.1 strain a 'variant under monitoring' (VUM). According to a 2023 definition by the WHO, a VUM is a variant which has undergone genetic changes that scientists believe could potentially affect the behaviour of the virus; early data suggests that this variant can grow faster or spread more easily than others, but this has not yet been confirmed. The evidence of the variant's impact on health, immunity or transmission is still unclear. While the NB.1.8.1 strain is still being researched, the evidence so far suggests that the strain may spread more easily, virologist Lara Herrero wrote for The Conversation on May 28. Researchers using lab-based models have found that of several variants tested, the new strain had the strongest ability to bind to human cell receptors. This suggests that the strain may 'infect cells more efficiently than earlier strains', Herrero wrote. 'It is more transmissible,' Subhash Verma, a professor of microbiology and immunology at the University of Nevada, Reno School of Medicine, told CBS News. Common symptoms of the NB.1.8.1 strain include a sore throat, cough, muscle aches, fever and nasal congestion. It can also cause gastrointestinal symptoms such as nausea and diarrhoea. Vaccines remain a powerful defence against COVID infections, severe sickness, hospitalisation and death, clinicians say. However, virologist Herrero wrote that besides spreading more easily, NB.1.8.1 may 'partially sidestep' immunity gained from the vaccines or prior infection. For now, health authorities say current COVID jabs are expected to be effective against this coronavirus variant and protect people from severe illness. Health experts worldwide say there is no evidence that the new strain of the coronavirus is more severe or deadly than any previous strain. However, it does appear to spread more easily. Since COVID spreads through airborne particles and droplets, the spread of the virus can be prevented by getting tested if symptoms show, wearing a mask and social distancing, clinicians have advised.